Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Methods Mol Biol ; 2639: 301-337, 2023.
Article de Anglais | MEDLINE | ID: mdl-37166724

RÉSUMÉ

Watson-Crick base-pairing of DNA allows the nanoscale fabrication of biocompatible synthetic nanostructures for diagnostic and therapeutic biomedical purposes. DNA nanostructure design elicits exquisite control of shape and conformation compared to other nanoparticles. Furthermore, nucleic acid aptamers can be coupled to DNA nanostructures to allow interaction and response to a plethora of biomolecules beyond nucleic acids. When compared to the better-known approach of using protein antibodies for molecular recognition, nucleic acid aptamers are bespoke with the underlying DNA nanostructure backbone and have various other stability, synthesis, and cost advantages. Here, we provide detailed methodologies to synthesize and characterize aptamer-enabled DNA nanostructures. The methods described can be generally applied to various designs of aptamer-enabled DNA nanostructures with a wide range of applications both within and beyond biomedical nanotechnology.


Sujet(s)
Aptamères nucléotidiques , Nanostructures , Acides nucléiques , Aptamères nucléotidiques/composition chimique , Nanostructures/composition chimique , ADN/composition chimique , Nanotechnologie/méthodes , Acides nucléiques/composition chimique , Conformation d'acide nucléique
2.
ACS Infect Dis ; 6(3): 366-378, 2020 03 13.
Article de Anglais | MEDLINE | ID: mdl-32011115

RÉSUMÉ

Killing more than one million people each year, tuberculosis remains the leading cause of death from a single infectious agent. The growing threat of multidrug-resistant strains of Mycobacterium tuberculosis stresses the need for alternative therapies. EthR, a mycobacterial transcriptional regulator, is involved in the control of the bioactivation of the second-line drug ethionamide. We have previously reported the discovery of in vitro nanomolar boosters of ethionamide through fragment-based approaches. In this study, we have further explored the structure-activity and structure-property relationships in this chemical family. By combining structure-based drug design and in vitro evaluation of the compounds, we identified a new oxadiazole compound as the first fragment-based ethionamide booster which proved to be active in vivo, in an acute model of tuberculosis infection.


Sujet(s)
Antituberculeux/pharmacologie , Conception de médicament , Éthionamide/pharmacologie , Mycobacterium tuberculosis/effets des médicaments et des substances chimiques , Oxadiazoles/pharmacologie , Protéines de répression/antagonistes et inhibiteurs , Animaux , Antituberculeux/composition chimique , Cristallographie aux rayons X , Découverte de médicament , Éthionamide/composition chimique , Femelle , Souris , Souris de lignée BALB C , Oxadiazoles/composition chimique , Oxadiazoles/isolement et purification , Relation structure-activité , Tuberculose/traitement médicamenteux
3.
Bioorg Med Chem Lett ; 22(23): 7227-31, 2012 Dec 01.
Article de Anglais | MEDLINE | ID: mdl-23063401

RÉSUMÉ

A novel series of combretastatin A-4 heterocyclic analogues was prepared by replacement of the B ring with indole, benzofurane or benzothiophene, attached at the C2 position. These compounds were evaluated for their abilities to inhibit tubulin assembly: derivative cis3b, having a benzothiophene, showed an activity similar to those of colchicine or deoxypodophyllotoxine. The antiproliferative and antimitotic properties of cis3b against keratinocyte cancer cell lines were also evaluated and the intracellular organization of microtubules in the cells after treatment with both stereoisomers of 3b was also determined, using confocal microscopy.


Sujet(s)
Antimitotiques/synthèse chimique , Composés hétérocycliques/composition chimique , Stilbènes/composition chimique , Antimitotiques/composition chimique , Antimitotiques/toxicité , Benzofuranes/composition chimique , Points de contrôle du cycle cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Prolifération cellulaire/effets des médicaments et des substances chimiques , Colchicine/pharmacologie , Humains , Indoles/composition chimique , Microscopie confocale , Microtubules/composition chimique , Microtubules/métabolisme , Stéréoisomérie , Stilbènes/synthèse chimique , Stilbènes/toxicité , Thiophènes/composition chimique
4.
Bioorg Med Chem Lett ; 22(14): 4555-60, 2012 Jul 15.
Article de Anglais | MEDLINE | ID: mdl-22727643

RÉSUMÉ

A total of 30 chalcone analogues was synthesized via a base catalyzed Claisen Schmidt condensation and screened for their in vitro antibacterial activity against Methicillin-sensitive Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) alone or in combination with non beta-lactam antibiotics namely ciprofloxacin, chloramphenicol, erythromycin, vancomycin, doxycycline and gentamicin. In the checkerboard technique, fractional inhibitory concentration indices (FICI) show that the following combinations like ciprofloxacin with 25 (4'-bromo-2-hydroxychalcone); doxycycline with 21 (4-hydroxychalcone); doxycycline with 25; and doxycycline with 4 (2',2-dihydroxychalcone) were synergistic against MRSA. In term SAR study, the relationship between chalcone structure and their antibacterial activity against S. aureus and synergy with tested antibiotics were discussed. Possible mechanisms for antibacterial activity of chalcones alone as well as the synergistic effect in combinations were proposed by molecular modeling studies, respectively. Combinations of chalcones with conventional antibiotics could be an effective alternative in the treatment of infection caused by MRSA.


Sujet(s)
Antibactériens/synthèse chimique , Staphylococcus aureus résistant à la méticilline/effets des médicaments et des substances chimiques , bêta-Lactames/synthèse chimique , Antibactériens/pharmacologie , Modèles moléculaires , Structure moléculaire , Relation structure-activité , bêta-Lactames/pharmacologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE